Answers are grounded in this paper and cite their sources.
These data support the use of BRCAPRO and genetic testing for BRCA1 and BRCA2 mutations in the management of high-risk African American families. Irrespective of ancestry, early age at diagnosis and a family history of breast and ovarian cancer are the most powerful predictors of mutation status and should be used to guide clinical decision making.
No takes yet. Share an insight, caveat, or question.
Nanda et al. (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: